Coronavirus Notebook: An Accidental Oxford Half Dose, And EU Finally Seals Moderna Vaccine Deal
Executive Summary
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.
You may also be interested in...
Coronavirus Notebook: UK Pledges To Donate Surplus Vaccines, UN Chief Wants Global Vaccination Plan
Janssen-Cilag has asked for a WHO Emergency Use Listing for its vaccine candidate, while azelastine and carrageenan are both showing promise as potential treatments for COVID-19.
COVID-19: EU Regulators To Restrict Veklury Use
The European Medicines Agency has clarified in which COVID-19 patients Gilead’s antiviral should be used.
COVID-19 Vaccines: AstraZeneca’s UK Study Not Good Enough For US FDA Authorization, Slaoui Says
Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.